ORENCIA details covers drugs, mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details

ORENCIA Market Forecast ORENCIA drug Insight

&ldquo;ORENCIA Market Size, Forecast, and Drug Insight &ndash; 2032&rdquo; report provides comprehensive insights about ORENCIA for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) in the seven major markets. A detailed picture of the ORENCIA in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 &ndash;2032 is provided in this report along with a detailed description of the ORENCIA. The report provides insights into the mechanism of action, dosage, and administration, as well as research and development, including regulatory milestones and other developmental activities. Furthermore, it also includes future market assessments, such as the ORENCIA market forecast analysis in the 7MM, SWOT analysis, analysts&rsquo; views, a comprehensive overview of market competitors, and a brief overview of other emerging therapies.
<h2 class="MsoNormal">Drug Summary</h2>
ORENCIA, developed by Bristol Myers Squibb (BMS), is a selective T-cell co-stimulation modulator used to treat moderately to severely active Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). It works by inhibiting T-cell activation through binding to CD80 and CD86, thereby preventing their interaction with CD28 &mdash; a key signal for full T-cell activation. This mechanism helps suppress inflammatory pathways involved in RA and PsA.
<ul>
<li class="MsoNormal">Mechanism of Action: Inhibits T-cell activation; reduces cytokines such as TNF-&alpha;, IL-2, and IFN-&gamma;.</li>
<li class="MsoNormal">Indications: Approved for adult RA, PsA, and polyarticular juvenile idiopathic arthritis (pJIA) in patients aged 2+.</li>
<li class="MsoNormal">Administration Options: Available as IV infusion, prefilled syringe, and auto-injector (SC).</li>
<li class="MsoNormal">Development: Co-developed in Japan by BMS and Ono Pharma; IV formulation managed by BMS, SC by Ono.</li>
</ul>
Despite reimbursement adjustments in 2021 due to ASP recalculation, ORENCIA remains a widely used immunomodulator, offering flexible administration and effective immune modulation for chronic inflammatory arthritis.
<h2 class="MsoNormal">Scope of the Report</h2>
The report provides insights into:
<ul>
<li class="MsoNormal">A comprehensive product overview including the ORENCIA description, mechanism of action, dosage and administration, research and development activities in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).</li>
<li class="MsoNormal">Elaborated details on ORENCIA regulatory milestones and other development activities have been provided in this report.</li>
<li class="MsoNormal">The report also highlights the ORENCIA research and development activities in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) across the United States, Europe, and Japan.</li>
<li class="MsoNormal">The report also covers the patents information with expiry timeline around ORENCIA.</li>
<li class="MsoNormal">The report contains forecasted sales of for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) till 2032.</li>
<li class="MsoNormal">Comprehensive coverage of the late-stage emerging therapies for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).</li>
<li class="MsoNormal">The report also features the SWOT analysis with analyst views for ORENCIA in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).</li>
</ul>
<h2 class="MsoNormal">Methodology</h2>
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight&rsquo;s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities' websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.
<h2 class="MsoNormal">ORENCIA Analytical Perspective by DelveInsight</h2>
In-depth ORENCIA Market Assessment
This report provides a detailed market assessment of ORENCIA for psoriatic arthritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
&nbsp;
ORENCIA Clinical Assessment
The report provides the clinical trials information of ORENCIA for psoriatic arthritis covering trial interventions, trial conditions, trial status, start and completion dates.
<h2 class="MsoNormal">Report Highlights&nbsp;</h2>
<ul>
<li class="MsoNormal">In the coming years, the market scenario for psoriatic arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;&nbsp;</li>
<li class="MsoNormal">The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ORENCIA dominance.</li>
<li class="MsoNormal">Other emerging products for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) are expected to give tough market competition to ORENCIA, and the launch of late-stage emerging therapies in the near future will significantly impact the market.</li>
<li class="MsoNormal">A detailed description of regulatory milestones and developmental activities provides the current development scenario of ORENCIA in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).</li>
<li class="MsoNormal">Our in-depth analysis of the forecasted sales data of ORENCIA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ORENCIA in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).</li>
</ul>
<h2 class="MsoNormal">Key Questions</h2>
<ul>
<li class="MsoNormal">What is the product type, route of administration and mechanism of action of ORENCIA?</li>
<li class="MsoNormal">What is the clinical trial status of the study related to ORENCIA in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) and study completion date?</li>
<li class="MsoNormal">What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ORENCIA development?</li>
<li class="MsoNormal">What are the key designations that have been granted to ORENCIA for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)?</li>
<li class="MsoNormal">What is the forecasted market scenario of ORENCIA for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)?</li>
<li class="MsoNormal">What are the forecasted sales of ORENCIA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?&nbsp;</li>
<li class="MsoNormal">What are the other emerging products available and how are these giving competition to ORENCIA for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)?</li>
<li class="MsoNormal">Which are the late-stage emerging therapies under development for the treatment of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)?</li>
</ul>

1. Report Introduction 
2. ORENCIA Overview&nbsp;
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy&nbsp;
2.3. Regulatory Milestones
2.4. Other Developmental Activities&nbsp;
2.5. Product Profile&nbsp;
3. Competitive Landscape (Marketed Therapies) 
4. Competitive Landscape (Late-stage Emerging Therapies) 
5. ORENCIA Market Assessment
5.1. Market Outlook of ORENCIA in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
5.2. 7MM Analysis
5.2.1. Market Size of ORENCIA in the 7MM for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
5.3. Country-wise Market Analysis
5.3.1. Market Size of ORENCIA in the United States for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
5.3.2. Market Size of ORENCIA in Germany for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
5.3.3. Market Size of ORENCIA in France for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
5.3.4. Market Size of ORENCIA in Italy for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
5.3.5. Market Size of ORENCIA in Spain for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
5.3.6. Market Size of ORENCIA in the United Kingdom for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
5.3.7. Market Size of ORENCIA in Japan for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
6. SWOT Analysis 
7. Analysts&rsquo; Views 
8. Appendix
8.1. Bibliography
8.2. Report Methodology
9. DelveInsight Capabilities 
10. Disclaimer 
11. About DelveInsight 
 
12. Report Purchase Options

“ORENCIA Drug Insight and Market Forecast – 2032” report provides comprehensive insights about ORENCIA for Psoriatic Arthritis (PsA) in the seven major markets. 

ORENCIA Drug Insight

ORENCIA Market Size, Forecast, and Drug Insight − 2032

ORENCIA Drug Insight and Market Forecast- 2032 report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition.